Guselkumab-treated patients with psoriatic arthritis achieved clinically meaningful improvements in general health outcomes measured with PROMIS-29 through 52 weeks: results from the phase 3 DISCOVER-1 trial
| Κύριοι συγγραφείς: | , , , , , , , , , , , |
|---|---|
| Μορφή: | Conference item |
| Γλώσσα: | English |
| Έκδοση: |
BMJ Publishing Group
2021
|
| _version_ | 1826270737974951936 |
|---|---|
| author | Orbai, AM Coates, LC Deodhar, A Helliwell, P Ritchlin, CT Kollmeier, A Hsia, EC Xu, XL Sheng, S Jiang, Y Liu, Y Han, C |
| author_facet | Orbai, AM Coates, LC Deodhar, A Helliwell, P Ritchlin, CT Kollmeier, A Hsia, EC Xu, XL Sheng, S Jiang, Y Liu, Y Han, C |
| author_sort | Orbai, AM |
| collection | OXFORD |
| description | |
| first_indexed | 2024-03-06T21:45:32Z |
| format | Conference item |
| id | oxford-uuid:4970a497-7a63-4d6a-a0ab-0e988caa696b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T21:45:32Z |
| publishDate | 2021 |
| publisher | BMJ Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:4970a497-7a63-4d6a-a0ab-0e988caa696b2022-03-26T15:31:46ZGuselkumab-treated patients with psoriatic arthritis achieved clinically meaningful improvements in general health outcomes measured with PROMIS-29 through 52 weeks: results from the phase 3 DISCOVER-1 trialConference itemhttp://purl.org/coar/resource_type/c_5794uuid:4970a497-7a63-4d6a-a0ab-0e988caa696bEnglishSymplectic ElementsBMJ Publishing Group2021Orbai, AMCoates, LCDeodhar, AHelliwell, PRitchlin, CTKollmeier, AHsia, ECXu, XLSheng, SJiang, YLiu, YHan, C |
| spellingShingle | Orbai, AM Coates, LC Deodhar, A Helliwell, P Ritchlin, CT Kollmeier, A Hsia, EC Xu, XL Sheng, S Jiang, Y Liu, Y Han, C Guselkumab-treated patients with psoriatic arthritis achieved clinically meaningful improvements in general health outcomes measured with PROMIS-29 through 52 weeks: results from the phase 3 DISCOVER-1 trial |
| title | Guselkumab-treated patients with psoriatic arthritis achieved clinically meaningful improvements in general health outcomes measured with PROMIS-29 through 52 weeks: results from the phase 3 DISCOVER-1 trial |
| title_full | Guselkumab-treated patients with psoriatic arthritis achieved clinically meaningful improvements in general health outcomes measured with PROMIS-29 through 52 weeks: results from the phase 3 DISCOVER-1 trial |
| title_fullStr | Guselkumab-treated patients with psoriatic arthritis achieved clinically meaningful improvements in general health outcomes measured with PROMIS-29 through 52 weeks: results from the phase 3 DISCOVER-1 trial |
| title_full_unstemmed | Guselkumab-treated patients with psoriatic arthritis achieved clinically meaningful improvements in general health outcomes measured with PROMIS-29 through 52 weeks: results from the phase 3 DISCOVER-1 trial |
| title_short | Guselkumab-treated patients with psoriatic arthritis achieved clinically meaningful improvements in general health outcomes measured with PROMIS-29 through 52 weeks: results from the phase 3 DISCOVER-1 trial |
| title_sort | guselkumab treated patients with psoriatic arthritis achieved clinically meaningful improvements in general health outcomes measured with promis 29 through 52 weeks results from the phase 3 discover 1 trial |
| work_keys_str_mv | AT orbaiam guselkumabtreatedpatientswithpsoriaticarthritisachievedclinicallymeaningfulimprovementsingeneralhealthoutcomesmeasuredwithpromis29through52weeksresultsfromthephase3discover1trial AT coateslc guselkumabtreatedpatientswithpsoriaticarthritisachievedclinicallymeaningfulimprovementsingeneralhealthoutcomesmeasuredwithpromis29through52weeksresultsfromthephase3discover1trial AT deodhara guselkumabtreatedpatientswithpsoriaticarthritisachievedclinicallymeaningfulimprovementsingeneralhealthoutcomesmeasuredwithpromis29through52weeksresultsfromthephase3discover1trial AT helliwellp guselkumabtreatedpatientswithpsoriaticarthritisachievedclinicallymeaningfulimprovementsingeneralhealthoutcomesmeasuredwithpromis29through52weeksresultsfromthephase3discover1trial AT ritchlinct guselkumabtreatedpatientswithpsoriaticarthritisachievedclinicallymeaningfulimprovementsingeneralhealthoutcomesmeasuredwithpromis29through52weeksresultsfromthephase3discover1trial AT kollmeiera guselkumabtreatedpatientswithpsoriaticarthritisachievedclinicallymeaningfulimprovementsingeneralhealthoutcomesmeasuredwithpromis29through52weeksresultsfromthephase3discover1trial AT hsiaec guselkumabtreatedpatientswithpsoriaticarthritisachievedclinicallymeaningfulimprovementsingeneralhealthoutcomesmeasuredwithpromis29through52weeksresultsfromthephase3discover1trial AT xuxl guselkumabtreatedpatientswithpsoriaticarthritisachievedclinicallymeaningfulimprovementsingeneralhealthoutcomesmeasuredwithpromis29through52weeksresultsfromthephase3discover1trial AT shengs guselkumabtreatedpatientswithpsoriaticarthritisachievedclinicallymeaningfulimprovementsingeneralhealthoutcomesmeasuredwithpromis29through52weeksresultsfromthephase3discover1trial AT jiangy guselkumabtreatedpatientswithpsoriaticarthritisachievedclinicallymeaningfulimprovementsingeneralhealthoutcomesmeasuredwithpromis29through52weeksresultsfromthephase3discover1trial AT liuy guselkumabtreatedpatientswithpsoriaticarthritisachievedclinicallymeaningfulimprovementsingeneralhealthoutcomesmeasuredwithpromis29through52weeksresultsfromthephase3discover1trial AT hanc guselkumabtreatedpatientswithpsoriaticarthritisachievedclinicallymeaningfulimprovementsingeneralhealthoutcomesmeasuredwithpromis29through52weeksresultsfromthephase3discover1trial |